« Back to Record
Citation APA

Eggermont, A. A., Testori, A., Suciu, S., Rutkowski, P., Kruit, W. H., Punt, C., Dummer, R., Sales, F., Keilholz, U., & de Schaetzen, G. (2016). Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity. European journal of cancer, 55, 111-121. doi:10.1016/j.ejca.2015.11.014


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/227057

Eggermont, A. A., Testori, A., Suciu, S., Rutkowski, P., Kruit, W. H., Punt, C., Dummer, R., Sales, F., Keilholz, U., & de Schaetzen, G. (2016). Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity. European journal of cancer, 55, 111-121. doi:10.1016/j.ejca.2015.11.014